Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 DegraderGlobeNewsWire • 10/09/24
Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech InvestorsSeeking Alpha • 10/06/24
Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV CongressGlobeNewsWire • 09/25/24
Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report?Zacks Investment Research • 09/06/24
Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 08/21/24
Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7GlobeNewsWire • 07/31/24
Kymera Therapeutics (KYMR) Surges 23.4%: Is This an Indication of Further Gains?Zacks Investment Research • 07/10/24
Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation DayGlobeNewsWire • 07/09/24
Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and EfficacyGlobeNewsWire • 07/08/24
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual MeetingGlobeNewsWire • 06/14/24
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual MeetingGlobeNewsWire • 06/01/24
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual MeetingGlobeNewsWire • 05/23/24
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual MeetingGlobeNewsWire • 05/22/24
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual MeetingGlobeNewsWire • 05/14/24